CRIS, Curis (formerly CBMI) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CRIS, Curis (formerly CBMI)

CRIS 1.260

-3.8%

3:58 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Norton who started this subject	8/19/2000 2:15:47 AM
From: Icebrg	Read Replies (1) of 668

MTSL The latest issue of MTSL (August, 17) "covers" the field of regenerative medicine. McCamant is as always very supportive of Curis. "Investment conclusion Although the long-range goals of regenerative medicine are still far away, we are impressed by the progress that has been made in the past few years and the number of new drug candidates that are in clinical testing. We are very optimistic about the field of regenerative medicine and the large market opportunities it addresses. Now is the time to make investment choices. We strongly recommend CRIS as a broad-based regenerative medicine company that is on the verge of receiving analyst support. CRIS had the foresight to anticipate the merging of stem cell, growth factor, and tissue engineering fields, and designed their merger to create a company with strong competencies in all these areas. We are impressed by the strategic forethought of CRIS’s leadership and by the depth of their pipeline. We continue to recommend STEM because of their leading stem cell technology."

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next